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A protocol for a discrete choice experiment: Understanding patient medicine
preferences for managing chronic non-cancer pain
Abstract
Introduction: High rates of chronic non-cancer pain (CNCP), concerns about adverse effects including
dependence among those prescribed potent pain medicines, the recent evidence supporting active rather
than passive management strategies and a lack of funding for holistic programme have resulted in
challenges around decision making for treatment among clinicians and their patients. Discrete choice
experiments (DCEs) are one way of assessing and valuing treatment preferences. Here, we outline a
protocol for a study that assesses patient preferences for CNCP treatment.
Methods and analysis: A final list of attributes (and their levels) for the DCE was generated using a
detailed iterative process. This included a literature review, a focus group and individual interviews with
those with CNCP and clinicians who treat people with CNCP. From this process a list of attributes was
obtained. Following a review by study investigators including pain and addiction specialists, pharmacists
and epidemiologists, the final list of attributes was selected (number of medications, risk of addiction,
side effects, pain interference, activity goals, source of information on pain, provider of pain care and outof-pocket costs). Specialised software was used to construct an experimental design for the survey. The
survey will be administered to two groups of participants, those from a longitudinal cohort of patients
receiving opioids for CNCP and a convenience sample of patients recruited through Australia's leading
pain advocacy body (Painaustralia) and their social media and website. The data from the two participant
groups will be initially analysed separately, as their demographic and clinical characteristics may differ
substantially (in terms of age, duration of pain and current treatment modality). Mixed logit and latent
class analysis will be used to explore heterogeneity of responses.
Ethics and dissemination: Ethics approval was obtained from the University of New South Wales Sydney
Human Ethics committee HC16511 (for the focus group discussions, the one-on-one interviews and
online survey) and HC16916 (for the cohort). A lay summary will be made available on the National Drug
and Alcohol Research Centre website and Painaustralia's website. Peer review papers will be submitted,
and it is expected the results will be presented at relevant pain management conferences nationally and
internationally. These results will also be used to improve understanding of treatment goals between
clinicians and those with CNCP.
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Abstract
Introduction High rates of chronic non-cancer pain
(CNCP), concerns about adverse effects including
dependence among those prescribed potent pain
medicines, the recent evidence supporting active rather
than passive management strategies and a lack of funding
for holistic programme have resulted in challenges around
decision making for treatment among clinicians and their
patients. Discrete choice experiments (DCEs) are one way
of assessing and valuing treatment preferences. Here,
we outline a protocol for a study that assesses patient
preferences for CNCP treatment.
Methods and analysis A final list of attributes (and
their levels) for the DCE was generated using a detailed
iterative process. This included a literature review, a
focus group and individual interviews with those with
CNCP and clinicians who treat people with CNCP. From
this process a list of attributes was obtained. Following a
review by study investigators including pain and addiction
specialists, pharmacists and epidemiologists, the final
list of attributes was selected (number of medications,
risk of addiction, side effects, pain interference, activity
goals, source of information on pain, provider of pain care
and out-of-pocket costs). Specialised software was used
to construct an experimental design for the survey. The
survey will be administered to two groups of participants,
those from a longitudinal cohort of patients receiving
opioids for CNCP and a convenience sample of patients
recruited through Australia’s leading pain advocacy body
(Painaustralia) and their social media and website. The
data from the two participant groups will be initially
analysed separately, as their demographic and clinical
characteristics may differ substantially (in terms of age,
duration of pain and current treatment modality). Mixed
logit and latent class analysis will be used to explore
heterogeneity of responses.
Ethics and dissemination Ethics approval was
obtained from the University of New South Wales Sydney
Human Ethics committee HC16511 (for the focus group
discussions, the one-on-one interviews and online survey)
and HC16916 (for the cohort). A lay summary will be
made available on the National Drug and Alcohol Research
Centre website and Painaustralia’s website. Peer review
papers will be submitted, and it is expected the results will
be presented at relevant pain management conferences
nationally and internationally. These results will also

Strengths and limitations of this study
►► This discrete choice experiment (DCE) will elucidate

how people with chronic non-cancer pain (CNCP)
value different treatments that include both medicines and holistic goals of pain management.
►► Our DCE will be conducted in two samples: an already recruited diverse cohort of people with CNCP
who have been prescribed opioids and a novel group
of people with CNCP who may not have been prescribed opioids, recruited via social media.
►► The samples will include the most common pain
conditions such as chronic back and neck problems,
arthritis and migraines.
►► The study will estimate marginal willingness to pay
for changes in number of medicines, level of pain
interference, risk of addiction and preference of service provider.
►► The preference DCE surveys will be undertaken in
Australia, which could affect generalisability to other
settings.

be used to improve understanding of treatment goals
between clinicians and those with CNCP.

Introduction
These are challenging times for both people
with chronic non-cancer pain (CNCP) and
those to whom they turn for treatment.
Despite a significant increase in opioids being
prescribed for CNCP in countries such as the
USA, Canada and Australia1–3 there is insufficient evidence on the long-term effectiveness
of use.4
Accompanying the increase in opioid
prescribing there has been a concurrent
increase in harms, with more than 64 000
opioid overdoses in the USA,5 1300 in
Australia6 in 2016 and 8440 in Europe.7
Responses to minimise harms associated with
pharmaceutical opioids include increased
regulatory controls such as prescription
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(GP) visits are at least partially covered by the Australian
Medicare and Pharmaceutical Benefits Schemes.
The discrete choice experiment (DCE) methodology allows for the identification of the preferences for
various treatment options and potential trade-offs that
individuals are willing to make. Moreover, DCEs have
been widely used in the health literature to elicit preferences from patient groups on health and non-health
outcomes.25 26 Studies that have utilised the DCE methodology to examine patient preferences for managing
CNCP have focused specifically on toleration of the
adverse effects of nonselective nonsteroidal anti-inflamatory drugs (NSAIDs) and selective COX-2 (cyclo-oxygenase) inhibitors,27 management of neuropathic pain,28
surgical or non-surgical approaches for low back pain29
; and acupuncture or infra-red treatments for low back
pain.30 These studies have often been limited to specific
treatments27–30 and to limited conditions.29 30 Here we
outline a study protocol to elicit patient preferences for
broader approaches to treatment for CNCP through use
of a DCE by extending the range of attributes to encompass a wider range of treatment alternatives including
holistic goals of pain management.

monitoring programme and limiting access to over-thecounter codeine in Canada, Australia and the USA.8
Other strategies have focused on improved clinical practice, including limiting maximum doses and prescriber
education.9 However, taken together with busy general
practitioners, a shortage of pain and addiction specialists,
fear of addiction and the lack of accessible and affordable alternatives for pain management this has led to
increased anxiety among many with CNCP.10
With chronic pain reported by approximately one-third
of the US population11 and 39% percent of a representative Australian sample,12 and potential rates of dependence varying between 1% and 24%13 among those who
are prescribed potent analgesic medicines, this represents
a sizeable challenge.
The benefits and harms of opioids for CNCP are
complex and contextual, and include factors such as age,
co-morbidities, health status, type and duration of pain,
concurrent medicines, patients’ ability and willingness
to self-manage. Under-treated CNCP adversely affects
patients’ well-being,10 but there are few data to inform
the range of treatment choices available, maximise treatment outcomes and patient adherence and minimise
unintended consequences. In addition, prescribing decisions and patients’ expectations are complicated by the
common side effects from many medicines used in CNCP,
the lack of long-term evidence on efficacy,14–17 the development of tolerance, fears of dependence and lack of
funding for non-drug-based treatment options.
Recent evidence suggests that active rather than passive
management strategies may ‘retrain the brain’ to reduce
pain,18 and that a multidisciplinary approach is likely to
produce the most optimal outcomes, but the cost and
availability of alternative treatments may affect patients’
treatment choices. In addition, cognitive behavioural
therapy has been found to help patients modify situational factors and multi-modal therapies that combine
exercise and related therapies with psychologically based
approaches also help reduce pain and improve function
more effectively than single modalities.19–21
Preferences of clinicians and patients can impact
prescribing patterns, uptake of interventions and treatment adherence, thus affecting the effectiveness of pain
management.22 It is important to understand why some
people with CNCP resort to treatments that are expensive or without evidence of efficacy; and alternatively,
why some stay on opioids long-term when not experiencing clinical benefit. For example, 34% of a cohort
of CNCP participants reported that there had been no
clinically significant change in their activity limitations,
symptoms, emotions and overall quality of life since
starting opioids.23 Significant proportions of the cohort
were using complementary or alternative interventions
for their pain which have limited or no evidence of efficacy in chronic pain.23 24 In addition, they often report
that attending physiotherapy, specialised exercise classes
or psychotherapy was often prohibitively expensive and
unfunded whereas medicines and general practitioner

Methods and analysis
Overview of the DCE
DCEs are a method of eliciting and quantifying preferences and exploring trade-offs between the attributes
(characteristics) of a treatment (or a good or service).
Attribute-based DCEs permit the exploration of preferences for treatment options while varying the levels
of each attribute.26 31 32 DCEs are based on Lancaster’s
economic theory of value (1966, 1971) and presume that
individuals derive utility (or well-being) not from the
good itself but rather from the attributes of that good.33 34
They rely on an individual’s knowledge or perceptions of
their own preferences, and on their ability to make tradeoffs between alternatives in the presence of constraints
such as money, time, availability and so on.
A DCE provides respondents with several hypothetical
but reasonable choice sets. Each choice set consists of at
least two alternatives that comprise a set of attributes each
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Aims
The aims of this study are to identify and value the factors
that influence important treatment decisions among
people living with CNCP, so we can better understand the
choices they make. Specifically, we will assess:
1. Preferences for medicines.
2. Impact on choice of potential side effects including
the possibility of addiction.
3. Willingness to pay (WTP) out of pocket for preferred
options, and the extent to which costs may be a barrier.
4. The extent to which having input into treatment is important.
5. The degree to which pain interference is tolerated.
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with various levels. Respondents are then asked to choose
their preferred alternative in each choice set.33 In making
a choice, the respondent identifies the alternative that
yields the highest utility to them. The attributes and their
levels are important, as they drive decision making. When
respondents make a choice, they make trade-offs between
the levels of the various attributes that can then be analysed with logistic regressions. When a cost attribute is
included, it is possible to indirectly estimate WTP values
for particular attributes of treatment.35–38 The dependent
variable in the logistic regression represents the probability of choosing one alternative with specific attributes
and levels over another. The independent variables are
the attributes and their levels. It is feasible to account
for heterogeneity through the use of covariates in mixed
logit (MXL) or latent class (LC) models.39 40
Theory
Consumer theory assumes deterministic behaviour, but
choice theory asserts that individual behaviour is intrinsically probabilistic (random). Individuals have a concept
of the value (indirect utility) for each choice, but the
researcher does not know all the factors that might affect
that choice. The utility estimate consists of the knowable
part and the random or unknowable parts. The random
part may be due to unobserved attributes, unobserved
preference variation, specification or measurement error,
or inter-individual differences in utility as a result of variation in tastes.33 41 The utility function in the context of the
DCE can be presented as follows:
	

Uij = Vij+ ϵij,j=1.....,J 

(1)

where individual i will choose alternative j if, and only
if, that alternative maximises their utility among all J alternatives. The utility (U) for individual i is conditional on
choice j and decomposed into explainable or systematic
Vij and non-explainable or random component εij. Vij can
be further broken down into Xjk, a vector of attributes of
the treatment, and Z, a vector of N characteristics of the
individual i, and β and γ are the respective coefficients
to be estimated for K attributes, with γn coefficients indicating the impact that the personal characteristics have
on choice.42
	

Vij =

K
∑
k=1

βk Xjk +

N
∑
n=1

γn Zin



(2)

where yij is equal to 1 if alternative j is chosen, and 0
otherwise and 1 is the choice if and only if
Vij + εij > Vim + εim for all j ≠ m which rearranges to
Vij - Vim > εim- εij.
Utilities are not observed, but by documenting the
choices made, utilities can be estimated.43 In addition (εim
− εij) is not observed directly and so it is only possible to
make observations up to a probability of occurrence with
some distribution or density function. It is the choice of
this distribution that affects interpretation of the probabilities.33 Different density functions for the unobserved
Shanahan M, et al. BMJ Open 2019;9:e027153. doi:10.1136/bmjopen-2018-027153

part of the utility εij lead to different families of probabilistic discrete choice models.
Undertaking a DCE requires several steps including
the selection of the relevant attributes and their
levels, obtaining a feasible design for the DCE survey,
constructing and administering the survey and determining the best-fitting model.
Patient and public involvement
The final survey tool (the DCE), including the framing
of the question, was developed after a focus group discussion and multiple one-on-one discussions with persons
who self-report as having CNCP. They were recruited
from members of Painaustralia. Painaustralia is Australia’s
leading pain advocacy body representing the interests of a
membership that includes health, medical, research and
consumer organisations it works to improve the quality
of life of people living with pain and to facilitate implementation of the National Pain Strategy Australia-wide.
As further described below, the important constructs
from this qualitative work informed the choice of attributes, levels and the final question. A lay summary of the
findings will be made available on the National Drug and
Alcohol Research Centre (NDARC) website and Painaustralia’s website.
Determining the attributes and levels for the DCE
The selection of attributes and their levels is a key step.
There is a need to balance the number of attributes to
adequately describe the good or service of interest; specifying too many attributes may hinder the respondents’
decision making. The number of attributes will vary with
the complexity of the good being considered, but typically
studies include four to eight attributes. Undertaking qualitative work to inform the selecting and framing improves
the relevance and applicability of the findings.44 45
Focus groups and telephone interviews with people living with
CNCP
As a first step in this study, a literature review was undertaken to identify the important constructs to explore in
subsequent focus groups and one-on-one discussions. The
intent was to recruit 20 to 25 participants to participate in
focus groups; however, it became apparent this was going
to be difficult due to health status of participants and location. Therefore, one focus group (N=3 participants) and
13 one-on-one telephone interviews were conducted with
people who had CNCP, to elicit views on topics such as
self-management, knowledge of pain mechanisms, brain
plasticity, relative importance of exercise, medicines,
choice of treatment provider and barriers and facilitators
to effective good treatment.
Telephone interviews with clinicians
In addition, interviews were conducted with a range of
clinicians including pain specialists, general practitioners
(urban and rural), clinical nurse specialists, physiotherapists and addiction specialists (N=8). Clinician interviews
3
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elicited additional information on barriers and facilitators to treatment and views on current modalities of treatment for CNCP.
Determining the list of attributes and levels
The final list of attributes included in the DCE experiment was generated using a detailed iterative process.
The first phase involved a literature review undertaken by
MSh to inform the development of list of possible factors
previously identified as influencing patient choice of
pain treatments. This list was reviewed and further developed among the broader pain and opioids in treatment
(POINT) study investigators that include pain and addiction specialists, pharmacists and epidemiologists.
These attributes developed in the first phase of the
study became the basis of (a) focus group discussions with
patients and (b) telephone interviews with clinicians. Two
authors (MSh and GC) reviewed the recorded transcripts
separately and independently analysed data thematically.
Attributes generated at this second phase included the
following themes: potential side effects; concurrent medicines; necessity to work/care for others; barriers; complementary medicine; multi-modal therapies; costs; time to
onset of effect; adherence/compliance; risk of addiction;
co-morbidities; and self-management.
In the final phase, this broader list was reviewed by the
broader POINT study investigator team, and a final list of
attributes (and their levels) was agreed. Attributes (and
number of levels) selected were number of medications
(4), risk of addiction (4), side effects (2), pain interference (4), activity goals, source of information on pain
(4), provider of pain care (4) and out-of-pocket costs (4).

Pilot study
The DCE design
Having selected the attributes, levels and number of alternatives (2), an experimental design for the survey was
generated. Given the number of attributes and levels, a
full factorial design including all possible combinations
of attributes and their levels was not feasible. Therefore,
a D-efficient experimental design that maximised model
statistical efficiency by minimising the parameter standard errors was generated using Ngene.46 The statistical
efficiency of the design is improved if some prior information about these parameters is available. This can be
coefficients from previous analysis or expert opinion.43 46
In the design for the pilot study, the prior coefficients
were set to zero.
Pilot-testing attributes and levels
A pilot study was conducted among 33 people living with
CNCP and who had been prescribed opioids. These data
were used to refine the final list of attributes and levels.
Specifically, the number of levels for the attribute ‘risk of
addiction to pain medicines’ was decreased from 4 to 2
levels (the two extremes), as respondents did not appear
to distinguish between the middle two levels. (See table 1
for final list of attributes and levels). The pilot testing was
also used assess the ease with which participants could
complete the experiment: 64% reported that it was easy/
very easy to complete the scenario questions, 27% found
it difficult and 9% found it very difficult.
Proposed study
Significant coefficients from the pilot study data (n=33)
were used in the final experimental design. An efficient

Table 1 Final attributes and levels
Attributes

Levels

Number of different medications taken on most days for pain
Known side effects of medications for pain

0, 2, 4,6
Mild, moderate/severe

Pain interference with daily activities

Never; sometimes; most of the time; always

Pain care is managed by

GP only; pain specialist; multidisciplinary pain
management team; myself

Risk of addiction to pain medication

Risk of 3 in 100 people or 25 in 100 people who are taking
strong pain medications*

Activity goals of treatment

Able to undertake activities of daily living; do exercises at
home, including walking, most days; participate in regular
exercise classes (gym/hydrotherapy classes); practice
mindfulness regularly

Source of information on pain and pain management

None; from a doctor; by reading/online; from a pain
management course
Out-of-pocket costs per month (ie, for medications, doctor, physio $50, $100, $200 or $300 per month
or psychologist visits, or other activities you would need to pay for
to help you manage your pain)
*Initial choice of four levels decreased to two after pilot study, see below.
GP, general practitioner.
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Table 2 Example of scenario
Treatment A

Treatment B

Pain medications per day
Known side effects of medications

2
Mild

4
Moderate/severe

Pain interference

Never

Never

Pain care is managed by

Myself

GP only

Risk of addiction to pain medications

3 in 100 people

25 in 100 people

Activity goals of treatment

Do exercises at home, including walking

Do exercises at home, including walking

Source of information on pain

From my doctor

By reading/online

Out-of-pocket costs per month
My choice is (please choose A or B)

300
□

300
□

GP, general practitioner.

design of 80 scenarios, with 10 blocks was generated for
the final design (each participant will be presented with
one block of eight scenarios). See table 2 for an example
of a scenario.
Participants and survey procedures
There is no agreement on the correct sample size
required for a DCE.47 However, research has shown that
in all DCE studies with efficient designs, model estimate
precision increases rapidly at sample sizes greater than
150 and then flattens out at around 300.48 It is also estimated that a minimum sample size of 200 respondents
per sub-group be used for studies involving an analysis
of differences between samples.49 The proposed DCE will
be administered to two groups of participants (see below)
with the sample size of each group being 200 participants
or greater. To examine the possibility of different treatment preferences in people living with CNCP we included
two distinct groups. The POINT cohort consist of participants who have been prescribed opioids for CNCP and
have been on long-term opioids for an average of 7
years at the time of the current study. The other sample
includes CNCP recruited online. These participants are
not necessarily prescribed opioids and we will examine
the differences in treatment preferences between people
prescribed and not prescribed opioids for CNCP.
Each participant will be randomly allocated to one of
10 blocks with each block having eight DCE questions. In
addition to the DCE questions, a range of demographic
and covariates (ie, age, gender, education, marital status)
and clinical characteristics (duration of pain, number
and type of medicines, pain interference scores) will be
collected.

opioids (including morphine, oxycodone, buprenorphine, methadone and hydromorphone) for CNCP
for greater than 6 weeks when recruited; competent in
English; mentally and physically able to participate in
telephone and self-complete interviews; and did not have
any serious cognitive impairments, as determined by the
interviewer at the time of screening. The POINT cohort
participants are interviewed annually over the phone,
and the DCE survey will be included as part of the fifthyear interview. Participants in the POINT cohort study
will be invited to participate in the survey and reasons for
not participating will be recorded; the first consecutive
33 interviews of the fifth-year interview were administered
the pilot study questionnaire and these participants will
not complete a second DCE. The DCE will be mailed to
participants prior to the date of interview along with an
explanation of the study aims and consent forms. The
DCE questionnaire will then be completed by the POINT
interviewers over the phone as part of the regular POINT
interview schedule. Covariates for the DCE will be drawn
from baseline data and the most recent interview.

Pain and opioids in treatment (POINT) prospective cohort study
The first source includes participants in POINT study, a
national prospective cohort of 1514 people living with
CNCP.23 The POINT study, currently in its fifth year,
recruited participants through community pharmacies
across Australia. Participants when recruited were: 18
years or older; living with CNCP (defined as pain lasting
longer than 3 months); taking prescribed Schedule 8

Online survey of people living with CNCP
A second group of respondents will be recruited online
through Painaustralia, a national peak body and pain
advocacy organisation, and through social media. This
group will be asked to complete an identical DCE survey
online (via Qualtrics, hosted at the University of New
South Wales (UNSW) Sydney), plus selected demographic, pain characteristics, type of medicines, questions
drawn from the POINT survey. Similar to the POINT
cohort, participants who are eligible for the online survey
will be aged 18 years or older, reside in Australia and are
living with CNCP (defined as pain lasting longer than 3
months). Unlike the POINT cohort, however, the online
sample will not be required to have been prescribed
Schedule 8 opioids (although this is not an exclusion in
the online survey).
Links to the online survey will be posted on the Painaustralia’s website, the NDARC website, and their associated Facebook pages, and twitter feeds. Recruitment
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will continue for 4 months (or until the current round
of interviews of the cohort are complete) with the objective of achieving at least 200 surveys completed online.
Respondents will be randomly allocated one of the 10
blocks, and demographic and covariates collected from
the POINT cohort will match.
Data analysis
The data from the two participant groups will be initially
analysed separately, as their demographic and clinical
characteristics may differ substantially (in terms of age,
duration of pain and current treatment modality). The
analysis of the DCE responses will be analysed using
Nlogit software.46 Initially a multinomial logit model will
be used. MXL and LC analysis will be used to explore
heterogeneity of responses. Number of medicines and
out-of-pocket costs will be treated as continuous variables;
all categorical variables will be effects coded which means
the constant will not be confounded with the grand mean
and coefficients for base levels can be estimated.50
Tables of coefficients for the levels and covariates will
be presented with relevant statistical measures including
pseudo r-squared, log likelihood test and the Akaike
information criterion (AIC) to test for goodness of fit
of the model. In addition, the marginal rate of substitution (the negative ratio between any two estimated coefficients) will be calculated. This will allow policy makers
and clinicians to understand the relative importance of
different attributes, and the respondents’ willingness to
give up some amount of one attribute in order to obtain
more of another.
Article summary
Strengths and limitations of this study
The DCE approach offers great potential for informing
clinicians as to patient preferences for pain management.
Where preferences do not align with current evidence, the
findings will provide an opportunity to develop strategies
for improving knowledge. If preferred options are those
that are known to be effective but also more expensive
for the patient, the results can be used to inform policy
makers. However, there are methodological limitations
that are common to all DCEs. In our study, one challenge
was to select attributes and levels that both reflect treatment for CNCP and outcomes but result in a practical
number to include. Our choice to use eight attributes
likely places higher cognitive demand on respondents but
we sought to mitigate this by only requiring each person
to complete eight DCE choices.
Our DCE will be conducted in a large, diverse sample
of people living with CNCP, including the most common
pain conditions such as chronic back and neck problems. This DCE differs from previous studies in that it will
elucidate how people value different CNCP treatments,
not just medicines or not just surgery. This study will also
permit the estimation of the marginal WTP for different
treatment options and outcomes. Although the marginal
WTP for preferred attributes will assist policy makers
6

generally, some of the results may not be generalisable
to resource-poor settings or countries without universal
healthcare systems.
Ethics and dissemination
A lay summary of the findings will be made available on
the NDARC website and Painaustralia’s website. Peer
review papers will be submitted, and it is expected the
results will be presented at relevant pain management
conferences nationally and internationally. These results
will also be used to improve understanding of treatment
goals between clinicians and those with CNCP goals.
Consent
Written consent was obtained from those who attended
the focus groups and verbal consent was obtained from
those who volunteered for phone interviews (researchers
were only aware of first name of telephone participants).
Consistent with UNSW ethics, for the online DCE survey,
consent was implicit in the decision to complete the
survey after reading the participation information sheet.
For the POINT cohort, consent has previously been
obtained from participants and the DCE is part of the
scheduled interview.
Acknowledgements We thank members of Painaustralia for their support of
this project through promoting it on their website and other social media, and for
inviting members to participate in focus groups and other discussions. We also
thank those who have completed the DCE survey and clinicians who contributed to
the discussion of barriers and facilitators for managing chronic pain.
Contributors MSh was lead author and responsible for the study design,
conducted the qualitative interviews and analysis, and the writing of the paper.
GC and BL were involved qualitative interviews and its analysis. Msc contributed
to the survey development and administration of the survey. MSh, BL, SN, MC and
GC were involved in defining and selecting the attributes and levels. All authors
provided detailed input to the paper.
Funding This was supported by the Australian National Health and Medical
Research Council (NHMRC) (APP 1100822) and the Australian Government. The
National Drug and Alcohol Research Centre, University of New South Wales Sydney
is supported by funding from the Australian Government, under the Substance
Misuse Prevention and Service Improvements Grant Fund. SN and GC are the
recipients of an NHMRC Research Fellowship (#1132433 and #1119992).
Competing interests BL and SN report investigator-driven untied educational
grants from Reckitt Benckiser/Indivior for studies of buprenorphine-naloxone and
buprenorphine depot, the development of an opioid-related behaviour scale and
a study of opioid substitution therapy uptake among chronic non-cancer pain
patients. BL has also received investigator-initiated untied educational grants
for post-marketing surveillance studies of opioids from Mundipharma Limited (a
tamper-resistant oxycodone formulation) and Seqirus (tapentadol). These funders
had no role in the design, conduct or interpretation of these studies. These studies
were unrelated to the current discrete choice experiment protocol or broader
pain and opioids in treatment study. SN has provided training around treatment of
codeine dependence for which her institution received funding from Indivior. GC
reports investigator-driven untied educational grants from Reckitt Benckiser for the
development of an opioid-related behaviour scale. MC reports receiving fees from
Mundipharma Limited for preparation and presentation of educational material.
Patient consent for publication Obtained.
Ethics approval Ethics approval was obtained from the UNSW Human Ethics
committee HC16511 (for the focus group discussions, the one-on-one interviews
and online survey) and HC16916 (for the cohort).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No additional data are available.
Shanahan M, et al. BMJ Open 2019;9:e027153. doi:10.1136/bmjopen-2018-027153

BMJ Open: first published as 10.1136/bmjopen-2018-027153 on 2 August 2019. Downloaded from http://bmjopen.bmj.com/ on August 22, 2019 at University of Wollongong. Protected by
copyright.

Open access

Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Blanch B, Pearson S-A, Haber PS. An overview of the patterns of
prescription opioid use, costs and related harms in Australia. Br J
Clin Pharmacol 2014;78:1159–66.
2. Fischer B, Argento E. Prescription opioid related misuse, harms,
diversion and interventions in Canada: a review. Pain Physician
2012;15(3 Suppl):ES191–203.
3. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription
opioid and heroin crisis: a public health approach to an epidemic of
addiction. Annu Rev Public Health 2015;36:559–74.
4. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of
long-term opioid therapy for chronic pain: a systematic review for a
national Institutes of health pathways to prevention workshop. Ann
Intern Med 2015;162:276–87.
5. National Institute of health, N. I. O. D. A. Overdoes death rates,
2017. Available: https://www.drugabuse.gov/related-topics/trends-
statistics/overdose-death-rates [Accessed 9 Nov 2017].
6. Australian Bureau of Statistics. Drug induced deaths in Australia: a
changing story. Canberra: A.B.o. Statistics, 2018.
7. European Monitoring Centre for Drugs and Drug Addiction. European
Drug Report 2017: Trends and Developments. Luxembourg:
P.O.o.t.E. Union, 2017.
8. Phillips J, Ford MA, Bonnie RJ. Committee on Pain Management
and Regulatory Strategies to Address Prescription Opioid Abuse,
Pain Management and the Opioid Epidemic: Balancing Societal and
Individual Benefits and Risks of Prescription Opioid Use. Washington
DC: The National Academies of Sciences, Engineering, Medicine,
2017.
9. Dowell D. Cdc guideline for prescribing opioids for chronic pain
— United States, 2016. Morbidity and Mortality Weekly Reports
2016;65:1–49.
10. Reuben DB, Alvanzo AAH, Ashikaga T, et al. National Institutes of
health pathways to prevention workshop: the role of opioids in the
treatment of chronic pain. Ann Intern Med 2015;162:295–300.
11. Johannes CB, Le TK, Zhou X, et al. The prevalence of chronic pain
in United States adults: results of an Internet-based survey. J Pain
2010;11:1230–9.
12. Campbell G, Darke S, Bruno R, et al. The prevalence and correlates
of chronic pain and suicidality in a nationally representative sample.
Aust N Z J Psychiatry 2015;49): :803–11.
13. Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse,
abuse, and addiction in chronic pain: a systematic review and data
synthesis. Pain 2015;156:569–76.
14. Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists
in the treatment of evoked neuropathic pain: systematic review of
randomized controlled trials. Eur J Pain 2006;10.
15. Furlan ADet al. Opioids for chronic noncancer pain: a metaanalysis of effectiveness and side effects. Can Med Assoc J
2006;174:1589–94.
16. Manchikanti L, Ailinani H, Koyyalagunta D, et al. A systematic review
of randomized trials of long-term opioid management for chronic
non-cancer pain. Pain Physician 2011;14:91–121.
17. Noble M, Treadwell JR, Tregear SJ, et al. Long-Term opioid
management for chronic noncancer pain. Cochrane Database Syst
Rev 2010;30.
18. Holliday SM. Managing the continuum between pain
and dependency in general practice. Drug Alcohol Rev
2011;30): :324–6.
19. Bernardy K, Klose P, Busch AJ, et al. Cognitive behavioural therapies
for fibromyalgia. Cochrane Database Syst Rev 2013;13.
20. Dowell D, Haegerich TM. C. R CDC guideline for prescribing opioids
for chronic pain —United states, 2016, in centres for disease control
and prevention MMWR. US Department of Hlath and Human
Services, 2016.
21. Williams ACdeC, Eccleston C, Morley S, et al. Psychological
therapies for the management of chronic pain (excluding headache)
in adults. Cochrane Database Syst Rev 2012;19.
22. Oshima Lee E, Emanuel EJ. Shared decision making to improve care
and reduce costs. N Engl J Med 2013;368:6–8.

Shanahan M, et al. BMJ Open 2019;9:e027153. doi:10.1136/bmjopen-2018-027153

23. Campbell G, Nielsen S, Bruno R, et al. The pain and opioids in
treatment study: characteristics of a cohort using opioids to manage
chronic non-cancer pain. Pain 2015;156:231–42.
24. Nielsen S, Campbell G, Peacock A. Health service utilisation by
people living with chronic non-cancer pain: findings from the pain
and opioids in treatment (point) study. Australian Health Review,
2015.
25. Clark MD, Determann D, Petrou S, et al. Discrete choice experiments
in health economics: a review of the literature. Pharmacoeconomics
2014;32:883–902.
26. De Bekker-Grob E, Ryan M, Gerard K. Discrete choice experiments in
health economics: a review of the literature. Health Economics, 2010.
27. Hauber AB, Arden NK, Mohamed AF, et al. A discrete-choice
experiment of United Kingdom patients' willingness to risk adverse
events for improved function and pain control in osteoarthritis.
Osteoarthritis Cartilage 2013;21:289–97.
28. Mühlbacher AC, Junker U, Juhnke C, et al. Chronic pain patients’
treatment preferences: a discrete-choice experiment. Eur J Health
Econ 2015;16): :613–28.
29. Kløjgaard ME, Manniche C, Pedersen LB, et al. Patient preferences
for treatment of low back Pain—A discrete choice experiment. Value
in Health 2014;17): :390–6.
30. Chen L-C, Cheng L-J, Zhang Y, et al. Acupuncture or low frequency
infrared treatment for low back pain in Chinese patients: a discrete
choice experiment. PLoS One 2015;10:e0126912.
31. Farrar S, Ryan M, Ross D, et al. Using discrete choice modelling in
priority setting: an application to clinical service developments. Soc
Sci Med 2000;50: :63–75.
32. Gerard K, Ryan M, Amaya-Amaya M. Introduction, in Using descrete
choice experiments to value health and health care. Dordrecht, The
Netherlands: Springer, 2008.
33. Amaya-Amaya M, Gerard K, Ryan M. Discrete choice experiments in
a nutshell, in Using discrete choice experiments to value health and
health care. Dordrecht, The Netherlands: Springer, 2008.
34. Louviere J, Hensher D, Swait J. Stated Choice Methods Analysis and
Application. Cambridge: Cambridge University Press, 2000.
35. Tockhorn-Heidenreich A, Ryan M, Hernández R. Discrete Choice
Experiments, in Patient Involvement in Health Technology
Assessment. In: Facey KM, Ploug Hansen H, Single ANV, eds.
Singapore: Singapore: Springer, 2017: 121–33.
36. Ryan M. Using conjoint analysis to take account of patient
preferences and go beyond health outcomes: an application to in
vitro fertilisation. Soc Sci Med 1999;48:535–46.
37. Ryan M, Kolstad J, Rockers P, et al. How to conduct a Discrete
Choice Experiment for health workforce recruitment and retention
in remote and rural areas: a user guide with case studies, in
CapacityPlus. World Bank and World Health Organization, 2012.
38. McIntosh E, Clarke P, Frew E, et al. Applied Methods of Cost-Benefit
Analysis in Health Care. Oxford University Press, 2010.
39. Goossens LMA, Utens CMA, Smeenk FWJM, et al. Should I stay
or should I go home? a latent class analysis of a discrete choice
experiment on hospital-at-home. Value Health 2014;17:588–96.
40. Lancsar E, Fiebig DG, Hole AR. Discrete choice experiments:
a guide to model specification, estimation and software.
Pharmacoeconomics 2017;35:697–716.
41. Ben Akiva M, Lerman S. Discrete choice analysis: theory and
applications to travel demand. Cambridge: MIT Press, 1985.
42. Green C, Gerard K. Exploring the social value of health-care
interventions: a stated preference discrete choice experiment. Health
Econ 2009;18:951–76.
43. Hensher D, Rose J, Greene W. Applied choice analysis a primer.
Cambridge: Cambridge University Press, 2005.
44. Coast J, Al-Janabi H, Sutton EJ, et al. Using qualitative methods for
attribute development for discrete choice experiments: issues and
recommendations. Health Econ 2012;21:730–41.
45. Kløjgaard ME, Bech M, Søgaard R. Designing a stated choice
experiment: the value of a qualitative process. Journal of Choice
Modelling 2012;5:1–18.
46. Rose J, Collins AT, Bliemer M, et al. Ngene 2018.
47. de Bekker-Grob EW, Donkers B, Jonker MF, et al. Sample size
requirements for discrete-choice experiments in healthcare: a
practical guide. Patient 2015;8:373–84.
48. Reed Johnson F, Lancsar E, Marshall D, et al. Constructing
experimental designs for discrete-choice experiments: report of
the ISPOR conjoint analysis experimental design good research
practices Task force. Value Health 2013;16:3–13.
49. Johnson R, Orme B. Sample size issues for conjoint analysis. Getting
started with conjoint analysis: strategies for product design and
pricing research. Madison: Research Publishers LLC, 2010: 57–66.
50. Hensher D, Rose J, Greene W. Applied Choice Analysis. 2th edn.
Cambridge Cambridge University Press, 2015.

7

BMJ Open: first published as 10.1136/bmjopen-2018-027153 on 2 August 2019. Downloaded from http://bmjopen.bmj.com/ on August 22, 2019 at University of Wollongong. Protected by
copyright.

Open access

